Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

Background The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past, including routine differential blood counts, T cell subset distribution patter...

Full description

Bibliographic Details
Main Authors: Teresa Amaral, Benjamin Weide, Graham Pawelec, Thomas Eigentler, Claus Garbe, Patrick Terheyden, Friedegund Meier, Kilian Wistuba-Hamprecht, Alexander Martens, Jonas Bochem, Janine Spreuer, Andrea Gaissler, Shannon Ottmann, Nikolaus Benjamin Wagner, Manfred Claassen
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e006802.full

Internet

https://jitc.bmj.com/content/11/6/e006802.full

Similar Items